AUSTIN, Texas, May 16, 2012 /PRNewswire/ -- Respira Therapeutics, Inc. (http://www.respiratherapeutics.com), developer of a breakthrough, excipient-free, high efficiency, dry powder inhaler (DPI) drug delivery technology for the treatment of respiratory and systemic diseases, announced today that Armando Anido, former President & CEO of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), was elected to the Respira Therapeutics, Inc. board of directors. Mr. Anido joined Auxilium in 2006 and grew sales from $42M in 2005, to over $260M in 2011, increasing market capitalization from $200M to over $900M during his tenure as CEO. Mr. Anido served as Executive Vice President, Sales and Marketing at MedImmune, Inc. from 1999 to 2006, and previously served in Senior Sales and Marketing positions at GlaxoWellcome and Lederle Laboratories.
"Armando Anido has an exceptionally strong commercial background in the pharmaceutical industry that combines an extensive network with experience that will enhance Respira's future success. This very relevant experience and his critical insight into the pharmaceutical markets and industry will greatly benefit Respira," said Bob Curtis, CEO of Respira Therapeutics.
"We are honored to have someone of Armando's experience and track record join the Respira board. It certainly adds additional validation of the potential impact for our technology in the marketplace," said David Blivin, Managing Director of Cottonwood Technology Fund, and Founding Investor of Respira.
"I believe Respira has developed a truly breakthrough high efficiency, lactose-free, dry powder inhaler (DPI) drug delivery technology that is poised to revolutionize the inhaled therapeutics market," said Anido. "I look forward to working with this dynamic team and the board to advance this technology to market."
About Respira Therapeutics, Inc.
Respira Therapeutics, Inc., founded in 2010 with offices in Austin, Texas, is a venture capital-backed, development stage company focused on commercializing its "best-in-class", excipient-free, high efficiency, dry powder inhaler (DPI) drug delivery technology for the treatment of respiratory and systemic diseases. To date, Respira has performed extensive invitro testing demonstrating its advanced DPI prototypes can deliver 2-5X more drug to the lung than commercially available DPI technologies. These seminal findings of superiority were recently confirmed in human studies. Respira is investigating applications of its breakthrough DPI technology in asthma, COPD, and other respiratory and systemic diseases and seeking partners for co-development opportunities.
Press Contacts: Robert M. Curtis, President and CEO Respira Therapeutics, Inc. email@example.com (650) 388 8222
SOURCE Respira Therapeutics, Inc.